MBRX Moleculin Biotech Inc

Price (delayed)

$2.51

Market cap

$13.39M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.16

Enterprise value

$3.26M

?
Relative Growth: Rel. Growth: 21
Relative Strength: Rel. Strength: 5
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 1

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. ...

Highlights
The EPS has surged by 98% year-on-year and by 92% since the previous quarter
MBRX's debt is down by 43% year-on-year and by 17% since the previous quarter
MBRX's net income is down by 27% year-on-year but it is up by 10% since the previous quarter

Key stats

What are the main financial stats of MBRX

MBRX stock price

How has the Moleculin Biotech stock price performed over time
Intraday
2.03%
1 week
-8.39%
1 month
1.21%
1 year
-85.1%
YTD
-24.17%
QTD
9.61%

Financial performance

How have Moleculin Biotech's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$27.03M
Net income
-$30.33M
Gross margin
N/A
Net margin
N/A
MBRX's net income is down by 27% year-on-year but it is up by 10% since the previous quarter
MBRX's operating income is down by 8% from the previous quarter and by 4.4% YoY

Price vs fundamentals

How does MBRX's price correlate with its fundamentals

Growth

What is Moleculin Biotech's growth rate over time

Valuation

What is Moleculin Biotech stock price valuation
P/E
N/A
P/B
0.88
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 98% year-on-year and by 92% since the previous quarter
MBRX's price to book (P/B) is 95% lower than its 5-year quarterly average of 18.7

Efficiency

How efficient is Moleculin Biotech business performance
Moleculin Biotech's return on assets has decreased by 34% YoY but it has increased by 7% QoQ

Dividends

What is MBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MBRX.

Financial health

How did Moleculin Biotech financials performed over time
Moleculin Biotech's total assets is 186% higher than its total liabilities
The total liabilities has dropped by 61% year-on-year but it has increased by 15% since the previous quarter
MBRX's quick ratio is up by 16% year-on-year
MBRX's debt is 99% smaller than its equity
The debt to equity has plunged by 100% YoY
MBRX's debt is down by 43% year-on-year and by 17% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.